Samsung Pharmaceutical Co., Ltd. (KOSE:A001360) acquired Shinhwa IM Co., Ltd. for KRW 3.7 billion on February 13, 2015. Under the terms of the deal, 0.05 million shares were acquired and payment were made with issued convertible bond of Samsung Pharmaceutical. For the period ended 2014, Shinhwa IM Co., Ltd. had total assets of KRW 1.52 billion, total stockholders' equity of KRW 1.06 billion, sales revenue of KRW 2.87 billion and net profit of KRW 182 million. The transaction was resolved by Board of Directors of Samsung Pharmaceutical on February 13, 2015.

Samsung Pharmaceutical Co., Ltd. (KOSE:A001360) completed the acquisition of Shinhwa IM Co., Ltd. on February 13, 2015.